The company Libytec Pharmaceutical Co. was founded in June 2008 with the aim of providing trustworthy proposals in the field of health with modern pharmaceutical formulations. It represents a modern approach in the field of Health, responding to modern requirements and has a considerable portfolio of drugs in many therapeutic categories.
Today Libytec circulates a innovative dermacosmetic product for the treatment of hair loss, CG 210.
As you know, severe hair loss in men and women is caused by different factors and although it may seem insignificant to others, it often has a significant emotional impact on those affected.
In many cases, severe hair loss, regardless of the cause, is due to the disruption of the normal hair life cycle.
CG210 is aimed at men and women who face hair loss problems. The worldwide unique and innovative mechanism of action of CG210 is distinguished in three parts:
The result is that if there are healthy hair follicles and the product is used normally, hair loss returns to normal in less than 44 days ensuring high satisfaction levels.
The action of CG 210 is due to the significant increase in the levels of BCL-2 and their restoration to near normal values. This is a protein considered a key regulator of apoptosis. At the same time, the amount of collagen around the hair follicles increases, reducing the diameter of the pores, thus facilitating better hair implantation and reducing contact with external infectious agents.
As for the safety of the product, the results of the tests show that CG 210 is non-irritating, hypoallergenic and does not show intolerance by the skin. In addition, the product is not oily, does not contain preservatives, dyes or glycol, has a low alcohol content and a low concentration of fragrance.
CG 210 is a combination of active ingredients with clinically proven effectiveness in hair growth and hair loss. Each box contains 80ml of topical solution in the form of a spray for external use. The product is available in different packages for men and women. Each box contains a pump.
The main ingredients are:
The product circulates internationally under the same name CG 210, is a product of research by the Swiss company Legacy and is manufactured in France.
CG210 was selected by Nikkei Health magazine as the recommended product for the treatment of hair loss in Japan.
It circulates in the major countries of Europe (such as France, Spain, Italy, Belgium) since the end of 2013 with the brand name Oenobiol from Sanofi. In France, in the first month of the product's launch, the average number of new users was 1,000 per week.
In Southeast Asia it circulates since October 2014 with the brand name CG 210 from Abbott Laboratories.
In Australia, Switzerland, Russia, Japan, Canada, China, Brazil, South Africa, Mexico, Argentina, Venezuela, Colombia, India, Korea and the Philippines, Galderma pharmaceutical took over its circulation with the brand name CG 210.
